Compare AZZ & BLLN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AZZ | BLLN |
|---|---|---|
| Founded | 1956 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Specialties | Medical Specialities |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.4B | 4.6B |
| IPO Year | 1994 | 2025 |
| Metric | AZZ | BLLN |
|---|---|---|
| Price | $153.24 | $93.91 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 5 | 7 |
| Target Price | ★ $141.80 | $126.71 |
| AVG Volume (30 Days) | 216.2K | ★ 795.0K |
| Earning Date | 04-22-2026 | 05-06-2026 |
| Dividend Yield | ★ 0.58% | N/A |
| EPS Growth | ★ 486.59 | 103.40 |
| EPS | ★ 1.72 | 0.48 |
| Revenue | ★ $1,061,817,000.00 | $305,112,000.00 |
| Revenue This Year | $7.03 | $46.29 |
| Revenue Next Year | $4.25 | $30.14 |
| P/E Ratio | ★ $87.99 | $194.44 |
| Revenue Growth | 14.53 | ★ 99.97 |
| 52 Week Low | $92.98 | $61.96 |
| 52 Week High | $162.20 | $150.44 |
| Indicator | AZZ | BLLN |
|---|---|---|
| Relative Strength Index (RSI) | 53.68 | 37.20 |
| Support Level | $132.06 | $73.46 |
| Resistance Level | $152.83 | $99.29 |
| Average True Range (ATR) | 3.87 | 6.90 |
| MACD | 0.19 | -4.42 |
| Stochastic Oscillator | 67.64 | 11.29 |
AZZ Inc is a provider of galvanizing and coil coating solutions to a broad range of end markets in North America. The company's operating segment consists of AZZ Metal Coatings, AZZ Precoat Metals, and AZZ Infrastructure Solutions. The company generates the majority of its revenue from the Precoat Metals segment, which provides coil coating application of protective and decorative coatings and related value-added downstream processing for steel and aluminum coils. Geographically, the company operates in the United States and Canada.
BillionToOne Inc is a molecular diagnostics company. It offers a portfolio of ultrasensitive tests covering prenatal genetic testing, cancer therapy selection, and response monitoring, which are based on its Quantitative Counting Templates (QCT) molecular counting platform. The company's product portfolio comprises UNITY, a portfolio of prenatal testing products that can conduct fetal risk analysis without requiring a paternal sample; Northstar Select, a ultrasensitive liquid biopsy test that provides insights into appropriate therapies for stage III or IV cancer patients; and Northstar Response, a tissue-free, pan-cancer, liquid biopsy test that measures several genomic loci uniquely methylated in cancer to provide insight into dynamic changes in therapy response.